Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kristy Bodden"'
Autor:
Juan Jose Rodriguez-Sevilla, Vera Adema, Kelly S. Chien, Sanam Loghavi, Feiyang Ma, Hui Yang, Guillermo Montalban-Bravo, Xuelin Huang, Xavier Calvo, Joby Joseph, Kristy Bodden, Guillermo Garcia-Manero, Simona Colla
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract In myelodysplastic syndromes (MDS), the IL-1β pathway is upregulated, and previous studies using mouse models of founder MDS mutations demonstrated that it enhances hematopoietic stem and progenitor cells’ (HSPCs’) aberrant differentiat
Externí odkaz:
https://doaj.org/article/a81dfcfa51e344c2979e0aded1947a8e
Autor:
Joseph D. Khoury, Kristy Bodden, Naveen Pemmaraju, Courtney D. DiNardo, Yesid Alvarado, Marina Konopleva, Brittany Yearby, Alessandra Ferrajoli, Carlos E. Bueso-Ramos, Gautam Borthakur, Guillermo Garcia-Manero, Tapan M. Kadia, Mahesh Swaminathan
Publikováno v:
Leukemia & Lymphoma. 60:2207-2213
Hypomethylating agents (HMA) are the standard of care for treatment of myelodysplastic syndromes (MDS). HMA-failure MDS has extremely poor prognosis. This study was designed to explore the utility of eltrombopag in post-HMA failure MDS patients. Pati
Autor:
Koji Sasaki, Koichi Takahashi, Guillermo Garcia-Manero, Naveen Pemmaraju, Sherry Pierce, Mohammad Azab, Prithviraj Bose, Farhad Ravandi, Courtney D. DiNardo, Hagop M. Kantarjian, Feng Wang, Elias Jabbour, Gautam Borthakur, Kiyomi Morita, Guillermo Montalban Bravo, Naval Daver, Maro Ohanian, Yesid Alvarado, Tapan M. Kadia, Kristy Bodden
Publikováno v:
Blood. 136:21-22
Introduction: Guadecitabine (SGI-110) is a next-generation hypomethylating agent (HMA) not metabolized by cytidine deaminase, a common pathway of decitabine deactivation. A multicenter phase II study has shown the clinical activity of guadecitabine i
Autor:
Xuelin Huang, Kristy Bodden, Tapan M. Kadia, Prithviraj Bose, Sherry Pierce, Guillermo Garcia-Manero, Hagop M. Kantarjian, Courtney D. DiNardo, Elias Jabbour, Steven M. Kornblau, Jorge E. Cortes, Graciela M. Nogueras-Gonzalez, Koichi Takahashi, Farhad Ravandi, Michael Andreeff, Gautam Borthakur, Guillermo Montalban-Bravo, Naval Daver, Yesid Alvarado, Maro Ohanian
Publikováno v:
Journal of Clinical Oncology. 35:7020-7020
7020 Background: Improving the current response and survival outcomes of patients with higher risk MDS and CMML is fundamental. Guadecitabine is a next generation hypomethylating agent with increased length of exposure compared to decitabine and clin
Autor:
Tapan M. Kadia, Farhad Ravandi, Xuelin Huang, Michael Andreeff, Elias Jabbour, Steven M. Kornblau, Guillermo Garcia-Manero, Prithviraj Bose, Maro Ohanian, Koichi Takahashi, Guillermo Montalban-Bravo, Ana Alfonso Pierola, Kristy Bodden, Sherry Pierce, Graciela M. Nogueras-Gonzalez, Kristina Littles, Courtney D. DiNardo, Naval Daver, Yesid Alvarado, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Jorge E. Cortes, Gautam Borthakur
Publikováno v:
Blood. 128:346-346
INTRODUCTION: Guadecitabine (SGI-110) is a next generation hypomethylating agent (HMA) formulated as a dinucleotide of decitabine and deoxyguanosine, with an increased length of exposure compared to decitabine due to reduced metabolism by cytidine de
Autor:
Khan, Maliha *, Kristy, Bodden *, Kadia, Tapan, Ferrajoli, Alessandra, Alvarado, Yesid, Borthakur, Gautam, Pemmaraju, Naveen, Konopleva, Marina, Garcia-Manero, Guillermo, DiNardo, Courtney
Publikováno v:
In Blood 3 December 2015 126(23):1691-1691